Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients
NCT07052994 · M.D. Anderson Cancer Center · PHASE1 · withdrawn · last registry update 2026-09-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI requested” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MEN1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-06Results posted on the registry: Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-07-06Also stopped (terminated): Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-05-05Also stopped (withdrawn): Children's Oncology Group, Cytarabine + Methotrexate (NCT07498465)
- 2025-10-08Phase 3 first posted: Syndax Pharmaceuticals, Revumenib + Placebo (NCT07211958)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision